-
Accelerating the pathway from drug discovery to patient treatment – pioneering advanced development methodologies for new TB drug regimens.
Read More.. -
Empowering African clinical trial sites through tailored local monitoring programmes.
Read More.. -
Developing limitless collaboration opportunities – academia, enterprises, governments, foundations, patient groups – a unique platform provided through a non-commercial broker!
Read More..
Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics
We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new drugs are central to any control strategy and the fastest route to tuberculosis elimination.
The consortium brings together a group of scientists from more that 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service.
Our Scientific Network
Executive Group Meets Face-to-Face in Amsterdam
As preparation for the teleconference that the PanACEA General Assembly will hold in June, the project’s Executive Group met in Amsterdam to discuss its plans, and upcoming deliverables and milestones on May 12th, 2017. The Executive Group met with representatives from Tanzania, South Africa, the UK, Germany, and the Netherlands. Collaborations, publications, and capacity development were important topics on the agenda. The Executive Group (EG) usually meets every two weeks through teleconference. This group acts as the supervisory body for the execution of the Project. The EG supervises the good managerial and scientific conduct of the various trials and ensures an optimal allocation of resources. The EG members look forward to share the discussed plans and ideas with the General Assembly on June...
PanACEA II meets in Cape Town
On 7 and 8 March 2017, the PanACEA consortium had their kick-off meeting in the sunny Cape Town in South Africa. A staggering number of 73 people attended the first day of the meeting. Important topics were the trials in the first two work packages, and PanACEA’s governance. Furthermore, time was set out for several partners to showcase scientific projects and give updates on their sites. On Wednesday 8 March the consortium had another full agenda with emphasis on the overarching trial in work package 3, plans for capacity development, and PanACEA’s future. Especially capacity development was a hot topic, resulting in a very vivid discussion. The capacity development plans are located at the core of PanACEA, as the sites are aiming to create an African network of transferring knowledge, expertise, and leadership. PanACEA now occupies itself with the preparation of its first trial, HIGHRIF, starting in July...
16.5 Million Euro for PanACEA II
PanACEA II has been granted 16.5 million euro in their drug development programme to shorten and simplify treatment of tuberculosis. On February 24th 2017, the coordinating team from Radboudumc Nijmegen, Martin Boeree and Rob Aarnoutse, have signed the PanACEA Grant Agreement with Radboudumc’s chairman of the board of directors, Leon van Halder. On February 27th, the European and Developing Countries Clinical Trials Partnership (EDCTP) has countersigned the agreement which results in the project’s official start on March 1st 2017. Rob Aarnoutse, Leon van Halder, and Martin Boeree signing the PanACEA II Grant Agreement Building on PanACEA I, the objectives of PanACEA II are to complete the optimization of existing drugs and to evaluate two novel agents. Combination regimens will be tested that will shorten and simplify treatment for both drug-sensitive and drug-resistant tuberculosis. Trials will be conducted at 11 sites throughout sub-Saharan Africa, empowering African scientists in all aspects of an integrated and comprehensive programme for drug development. The capacity development programme, which stems from PanACEA I, will be...